Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has appointed VP corporate business development Prof. Itzhak Krinsky as chairman of Teva Japan and Teva South Korea and head of business development Asia-Pacific. He will report directly to Teva president and CEO Dr. Jeremy Levin.
Krinsky will take up his post mid-October, and will be based in Tokyo. He will be responsible for overseeing Teva’s generic and branded pharmaceuticals businesses in Japan and South Korea, as well as managing business development in the Asia-Pacific region.
Krinsky is succeeding Moshe Manor, who is retiring, after 28 years at the company.
Levin said, “As part of our global strategic plan and in response to our growing presence in Asia-Pacific, we are positioning this part of our business to focus on the strong growth prospects in this region. We are committed to aggressively competing in these markets."
Teva has been expanding its Japanese operations in recent years, acquiring Taiyo Pharmaceuticals Ltd. and Taisho Pharmaceutical Industries Ltd. and buying out its partner in Teva-Kowa Pharma, Kowa Company Ltd. Japan's healthcare market is the second largest in the world after the US, and the country is dealing with high healthcare costs as its population ages, making it an attractive market for pharmaceutical companies.
Published by Globes [online], Israel business news - www.globes-online.com - on September 13, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012